|
Eine Ebene nach oben |
Gruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 10
2022
Sommerhäuser, G.; Kurreck, A.; Stintzing, S.; Heinemann, V.; Fischer von Weikersthal, L.; Dechow, T.; Kaiser, F.; Karthaus, M.; Schwaner, I.; Fuchs, M.; König, A.; Roderburg, C.; Hoyer, I.; Quante, M.; Kiani, A.; Fruehauf, S.; Müller, L.; Reinacher-Schick, A.; Ettrich, T. J.; Stahler, A. und Modest, D. P.
(2022):
Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer.
In: BMC Cancer, Bd. 22, Nr. 1, 820
2021
Haas, M.; Waldschmidt, D. T.; Stahl, M.; Reinacher-Schick, A.; Freiberg-Richter, J.; Fischer von Weikersthal, L.; Kaiser, F.; Kanzler, S.; Frickhofen, N.; Seufferlein, T.; Dechow, T.; Mahlberg, R.; Malfertheiner, P.; Illerhaus, G.; Kubicka, S.; Abdul-Ahad, A.; Snijder, R.; Kruger, S.; Westphalen, C. B.; Held, S.; Bergwelt-Baildon, M. von; Boeck, S. und Heinemann, V.
(2021):
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method.
In: European Journal of Cancer, Bd. 146: S. 95-106
2020
Fietkau, R.; Grützmann, R.; Wittel, U. A.; Croner, R. S.; Jacobasch, L.; Neumann, U. P.; Reinacher-Schick, A.; Imhoff, D.; Boeck, S.; Keilholz, L.; Oettle, H.; Hohenberger, W. M.; Golcher, H.; Bechstein, W. O.; Uhl, W.; Pirkl, A.; Adler, W.; Semrau, S.; Rutzner, S.; Ghadimi, M. und Lubgan, D.
(2020):
R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007 +/- trial.
In: Strahlentherapie und Onkologie, Bd. 197, Nr. 1: S. 8-18
2018
Haas, M.; Siveke, J. T.; Schenk, M.; Lerch, M. M.; Caca, K.; Freiberg-Richter, J.; Fischer von Weikersthal, L.; Kullmann, F.; Reinacher-Schick, A.; Fuchs, M.; Kanzler, S.; Kunzmann, V.; Ettrich, T. J.; Kruger, S.; Westphalen, C. B.; Held, S.; Heinemann, V. und Böck, S.
(2018):
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
In: European Journal of Cancer, Bd. 94: S. 95-103
2017
Geissler, M.; Martens, U.; Knorrenschild, J. R.; Greeve, J.; Florschütz, A.; Tannapfel, A.; Mönnich, H.; Ettrich, T.; Kanzler, S.; Büchner-Steudel, P.; Heinemann, V.; Held, S.; Reinacher-Schick, A.; Hebart, H.; Atzpodien, J.; Egger, M.; Lindig, U. und Müller, C.
(2017):
mFOLFOXIRI plus Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO-KRK0109).
In: Oncology Research and Treatment, Bd. 40: S. 123
Haas, M.; Böck, S.; Siveke, J. T.; Schenk, M.; Lerch, M.; Caca, K.; Freiberg-Richter, J.; Fischer von Weikersthal, L.; Kullmann, F.; Reinacher-Schick, A.; Fuchs, M.; Ettrich, T. J.; Kanzler, S.; Kunzmann, V.; Kruger, S.; Westphalen, C. B.; Held, S. und Heinemann, V.
(2017):
Efficacy of gemcitabine plus erlotinib for rash-positive metastatic pancreatic cancer patients eligible for treatment with FOLFIRINOX - a prospective phase II trial of the "Arbeitsgemeinschaft Internistische Onkologie" - AIO.
In: Oncology Research and Treatment, Bd. 40: S. 207-208
Geissler, M.; Martens, U. M.; Knorrenschield, R.; Greeve, J.; Florschütz, A.; Tannapfel, A.; Wessendorf, S.; Seufferlein, T.; Kanzler, S.; Heinemann, V.; Held, S. und Reinacher-Schick, A.
(2017):
mFOLFOXIRI plus panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO-KRK0109).
In: Annals of Oncology, Bd. 28
2016
Modest, Dominik P.; Ricard, Ingrid; Heinemann, Volker; Hegewisch-Becker, S.; Schmiegel, W.; Porschen, R.; Stintzing, Sebastian; Graeven, U.; Arnold, D.; Fischer von Weikersthal, L.; Giessen-Jung, Clemens; Stahler, A.; Schmoll, H. J.; Jung, A.; Kirchner, T.; Tannapfel, A. und Reinacher-Schick, A.
(September 2016):
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
In: Annals of Oncology, Bd. 27, Nr. 9: S. 1746-1753
[PDF, 410kB]
2013
Giessen, C.; Graeven, U.; Laubender, Rüdiger P.; Modest, D. P.; Schulz, C.; Porschen, R.; Schmiegel, W.; Reinacher-Schick, A.; Hegewisch-Becker, S.; Stintzing, S. und Heinemann, V.
(2013):
Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group.
In: Annals of Oncology, Bd. 24, Nr. 12: S. 3051-3055
2012
Modest, D. P.; Reinacher-Schick, A.; Stintzing, S.; Giessen, C.; Tannapfel, A.; Laubender, Rüdiger P.; Brodowicz, T.; Knittelfelder, R.; Vrbanec, D.; Schmiegel, W.; Heinemann, V. und Zielinski, C. C.
(2012):
Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
In: Anticancer Drugs, Bd. 23, Nr. 6: S. 666-673